Drug Oncology

Talzenna

Payments companies reported to CMS as associated with Talzenna. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$3.7Massociated payments (2023-2025)

11,462clinicians with associated payments

6companies reporting

By year

2023 $1.3M

2024 $1.2M

2025 $1.2M

Payments reported as associated with Talzenna, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Urology $920K

Hematology & Oncology $894K

Medical Oncology $737K

Diagnostic Radiology $510K

Family $120K

Body Imaging $88K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Talzenna

These are the largest totals companies reported as associated with Talzenna. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Pedro Barata	New Orleans, LA	Hematology & Oncology	$232,286.38
Amit Mehta	Cary, NC	Hematology & Oncology	$102,151.06
Jennifer Uyeda	Boston, MA	Diagnostic Radiology	$97,930.00
Yingbing Wang	San Francisco, CA	Diagnostic Radiology	$96,970.00
Stephen Freedland	West Hollywood, CA	Urology	$96,443.38
Michael Steigner	Boston, MA	Diagnostic Radiology	$94,670.00
Cheryl Sadow	Boston, MA	Body Imaging	$87,750.00
Joan Prowda	Philadelphia, PA	Diagnostic Radiology	$87,380.00
Joshua Lang	Madison, WI	Medical Oncology	$83,265.64
Jacek Pinski	Los Angeles, CA	Medical Oncology	$75,323.38

Prescribed Talzenna?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.